Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.

Previous studies have identified several potential predisposing factors, including ventricular aneurysm, low LVEF, and alterations in coagulation and inflammatory markers. The relative weight of these ...

Novartis has announced its acquisition of Anthos Therapeutics, a Boston-based biopharmaceutical company focused on developing abelacimab, an inve ...

We excluded studies with patients with edge-to-edge MVr, those with pre-existing indication for anti-coagulation, if patients received a concomitant cardiac procedure requiring anti-coagulation and ...